Furthermore, recent reports highlight dinaciclib, a well-known CDK inhibitor, now recognized for its novel activity in BET suppression.487 The dual inhibitory capability of dinaciclib presents a potential strategy to counteract BET resistance in AML treatment.487 These developments underscore the potential of these drugs to achieve market approval for broad clinical use. This evidence concerns the gene DNER and acute myeloid leukemia.